Luis Antonio Ruiz-Avila
Directeur Général chez Leukos Biotech SL
Profil
Luis Antonio Ruiz-Avila is currently the Chief Executive Officer at Leukos Biotech SL since 2019 and at Immuni Therapeutics SL since 2020.
He is also the Chairman at Aquilón Cyl SL and a Director at Kintsugi Therapeutics.
Previously, he served as the Chief Executive Officer at Archivel Farma SL.
He was also the Director at Asociacion De Empresas Biotecnologicas in 2008.
Additionally, he worked as a Principal at Icahn School of Medicine at Mount Sinai.
Prior to that, he was a Project Manager at Almirall Ltd.
from 1997 to 2001.
Dr. Ruiz-Avila obtained his undergraduate and doctorate degrees from the University of Barcelona.
Postes actifs de Luis Antonio Ruiz-Avila
| Sociétés | Poste | Début |
|---|---|---|
Aquilón Cyl SL
 Aquilón Cyl SL Medical/Nursing ServicesHealth Services Aquilón Cyl SL develops vaccines and probiotics to combat swine diseases. It develops the findings and inventions of Spanish research, basically in the veterinary medicine field. The company was founded by Nistal Pedro Miguel Rubio in March, 2012 and is headquartered in Leon, Spain. | Président | - |
Immuni Therapeutics SL
 Immuni Therapeutics SL BiotechnologyHealth Technology Immuni Therapeutics SL is a Spanish company that develops vaccines against COVID-19 and other viruses. The private company is based in Badalona, Spain. Immuni Therapeutics is promoted by Archivel Farma, the owner of the Ruti vaccine, which has yielded the rights for its development and commercialization to the new company. The Ruti vaccine is unique as it is based on the potentiation of the "trained innate immunity" in the patient, making it compatible with other vaccines and better adapted to the possible mutations of the virus or the arrival of new ones. Luis Antonio Ruiz-Avila has been the CEO of the company since 2020. | Directeur Général | 01/09/2020 |
Leukos Biotech SL
 Leukos Biotech SL Pharmaceuticals: MajorHealth Technology Leukos Biotech SL develops of new treatments for acute myeloid leukaemia and other haematological malignancies. The company was founded by Ruth Munoz Risueño in 2015 and is headquartered in Barcelona, Spain. | Directeur Général | 01/10/2019 |
Kintsugi Therapeutics
 Kintsugi Therapeutics Pharmaceuticals: MajorHealth Technology Kintsugi Therapeutics is a biomedical start-up based in Barcelona, Spain. The Spanish company focuses on developing innovative therapies for the treatment of liver conditions and other pathologies by targeting the regulation of endoplasmic reticulum stress. The company's lead candidate is a first-in-class endoplasmic reticulum stress inhibitor being developed for the treatment of non-alcoholic steatohepatitis (NASH). The company was founded by Carmen Herrero and Marc Cusachs, with Carmen Herrero serving as the CEO since incorporation. | Directeur/Membre du Conseil | - |
Anciens postes connus de Luis Antonio Ruiz-Avila
| Sociétés | Poste | Fin |
|---|---|---|
Asociacion De Empresas Biotecnologicas
 Asociacion De Empresas Biotecnologicas BiotechnologyHealth Technology Asociacion De Empresas Biotecnologicas operates as a Spanish biotechnology company. The private company is based in Madrid, Spain. | Directeur/Membre du Conseil | 01/01/2008 |
Almirall Ltd.
 Almirall Ltd. Pharmaceuticals: OtherHealth Technology Almirall Ltd. is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain. In Almirall they research, develop, produce and market proprietary R&D medicines and those under licence with the aim of improving people's health and wellbeing. They devote big human and economic resources to constant research into new drugs and to obtaining effective and safe products against discomfort and disease. | Corporate Officer/Principal | 01/01/2001 |
Archivel Farma SL
 Archivel Farma SL Miscellaneous Commercial ServicesCommercial Services Archivel Farma SL provides research and development services to the pharmaceutical sector. It focuses on TB, more specifically, on the treatment of the latent TB infection diseases. The firm is association with the Germans Trias i Pujol Research Institut of Health Sciences and the Germans Trias i Pujol University Hospital has developed RUTI, the first therapeutic vaccine against TB. The company was founded in 2005 by José Martínez, Pere-Joan Cardona i Iglèsias, Jaume Amat i Reira and Isabel Amat i Riera and is headquartered in Badalona, Spain. | Directeur Général | - |
| Icahn School of Medicine at Mount Sinai | Corporate Officer/Principal | - |
Formation de Luis Antonio Ruiz-Avila
| University of Barcelona | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Archivel Farma SL
Archivel Farma SL Miscellaneous Commercial ServicesCommercial Services Archivel Farma SL provides research and development services to the pharmaceutical sector. It focuses on TB, more specifically, on the treatment of the latent TB infection diseases. The firm is association with the Germans Trias i Pujol Research Institut of Health Sciences and the Germans Trias i Pujol University Hospital has developed RUTI, the first therapeutic vaccine against TB. The company was founded in 2005 by José Martínez, Pere-Joan Cardona i Iglèsias, Jaume Amat i Reira and Isabel Amat i Riera and is headquartered in Badalona, Spain. | Commercial Services |
Almirall Ltd.
Almirall Ltd. Pharmaceuticals: OtherHealth Technology Almirall Ltd. is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain. In Almirall they research, develop, produce and market proprietary R&D medicines and those under licence with the aim of improving people's health and wellbeing. They devote big human and economic resources to constant research into new drugs and to obtaining effective and safe products against discomfort and disease. | Health Technology |
Asociacion De Empresas Biotecnologicas
Asociacion De Empresas Biotecnologicas BiotechnologyHealth Technology Asociacion De Empresas Biotecnologicas operates as a Spanish biotechnology company. The private company is based in Madrid, Spain. | Health Technology |
Aquilón Cyl SL
Aquilón Cyl SL Medical/Nursing ServicesHealth Services Aquilón Cyl SL develops vaccines and probiotics to combat swine diseases. It develops the findings and inventions of Spanish research, basically in the veterinary medicine field. The company was founded by Nistal Pedro Miguel Rubio in March, 2012 and is headquartered in Leon, Spain. | Health Services |
Immuni Therapeutics SL
Immuni Therapeutics SL BiotechnologyHealth Technology Immuni Therapeutics SL is a Spanish company that develops vaccines against COVID-19 and other viruses. The private company is based in Badalona, Spain. Immuni Therapeutics is promoted by Archivel Farma, the owner of the Ruti vaccine, which has yielded the rights for its development and commercialization to the new company. The Ruti vaccine is unique as it is based on the potentiation of the "trained innate immunity" in the patient, making it compatible with other vaccines and better adapted to the possible mutations of the virus or the arrival of new ones. Luis Antonio Ruiz-Avila has been the CEO of the company since 2020. | Health Technology |
Leukos Biotech SL
Leukos Biotech SL Pharmaceuticals: MajorHealth Technology Leukos Biotech SL develops of new treatments for acute myeloid leukaemia and other haematological malignancies. The company was founded by Ruth Munoz Risueño in 2015 and is headquartered in Barcelona, Spain. | Health Technology |
Kintsugi Therapeutics
Kintsugi Therapeutics Pharmaceuticals: MajorHealth Technology Kintsugi Therapeutics is a biomedical start-up based in Barcelona, Spain. The Spanish company focuses on developing innovative therapies for the treatment of liver conditions and other pathologies by targeting the regulation of endoplasmic reticulum stress. The company's lead candidate is a first-in-class endoplasmic reticulum stress inhibitor being developed for the treatment of non-alcoholic steatohepatitis (NASH). The company was founded by Carmen Herrero and Marc Cusachs, with Carmen Herrero serving as the CEO since incorporation. | Health Technology |
